Swiss drugmakers Roche and Novartis underscored how their portfolios are increasingly clashing on the commercial battlefield, announcing new data on drugs aimed at capturing market share from each other.

Indivior Plc raised the company’s full-year 2019 forecasts as the embattled British drugmaker’s best-selling opioid addiction drug Suboxone fared better than expected in the face of competition from copycats.

Despite numerous FDA approvals of biosimilars, they have not yet gained a significant stake in the U.S. marketplace, according to a recent analysis published in Forbes.

Eli Lilly and Co.’s migraine treatment Emgality became the first drug to gain U.S. approval for decreasing the frequency of episodic cluster headache attacks.

The U.S. FDA declined to approve a pre-filled syringe version of Regeneron Pharmaceuticals Inc.’s blockbuster eye drug Eylea.

Days after rejecting Regeneron’s attempt to secure a supplemental approval for Eylea, the FDA approved a new dosing label for the drug in wet age-related macular degeneration (wet AMD).

The Janssen Pharmaceutical Companies of Johnson & Johnson confirmed top-line data from the Phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS) trial of the first investigational long-acting injectable two-drug regimen for the treatment of HIV-1.

GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world’s leading AIDS conference by showcasing detailed results from its new two-drug treatment.

Britain’s Indivior was subpoenaed by the California Department of Insurance over its blockbuster opioid addiction treatment Suboxone Film, which is rapidly losing market share due to stiff competition from generic versions.

Novo Nordisk will take aim at Eli Lilly in the growing diabetes market after an advisory panel to the U.S. FDA gave the green light to its semaglutide drug.